Publications

2026

81. Kim EJ, Lee Y, Ryu J, Kim H, Park J, Lee J. Cell-penetrating peptides for therapeutic applications: emerging design strategies and future directions. Org. Biomol. Chem. 2026, 24, 1938-1964.

2024

80. Kim EJ, Jeon HB, Kang MJ,* Lee J* Dynamic imaging of lipid droplets in cells and tissues by using dioxaborine barbiturate-based fluorogenic probes. Anal. Chem. 2024, 96, 8356-8364. (*co-corresponding authors)

79. The Atomwise AIMS Program (Wallack et al.) AI is a viable alternative to high throughput screening: a 318-target study. Sci. Rep. 2024, 14, 7526.

2023

78. Park JE**, Lee J**, Ok S, Byun S, Yoon SE, Kim YJ, Kang MJ Wg/Wnt1 and Erasp link ER stress to proapoptotic signaling in an autosomal dominant retinitis pigmentosa model. Exp. Mol. Med. 2023, 55, 1544-1555 (**co-first authors)

77. Song D**, Lee JY**, Park EC, Choi NE, Nam HY, Seo J*, Lee J* Structure-activity relationship analysis of activity-based probes targeting HTRA family of serine proteases. Bioorg. Med. Chem. Lett. 2023, 87, 129259 (**co-first authors, *co-corresponding authors)

2022

76. Choi NE, Kim EJ, Lee J. A fluorescent molecular rotor for the in situ imaging of latent fingerprints. RSC Adv. 2022, 12, 33180-33186

75. Kim S**, Lee JY**, Choi J, Nam HY, Seo J*, Lee J* Structure-activity relationship of mitochondria-targeting peptoids. Pept. Sci. 2022, 114, e24239. (**co-first authors & *co-corresponding authors)

2021

74. Manh NV, Hoang V, Ngo VTH, Ann J, Jang T-H, Ha J-H, Song JY, Ha H-J, Kim H, Kim Y-H, Lee J, Lee J. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer’s agents by the combination of pharmacophore-based and structure-based design. Eur. J. Med. Chem. 2021, 226, 113819.

73. Kim TH, Morshed MN, Londhe AM, Lim JW, Jung SY, Yang H, Cho S, Cho SJ, Hwang H, Lim SM, Lee JY, Lee J*, Pae AN* The translocator protein ligands as mitochondrial functional modulators for the potential anti-Alzheimer agents. J. Enzyme Inhib. Med. Chem. 2021, 36, 831-846 (*co-corresponding authors)

72. Choi NE, Lee JY, Park EC, Lee JH, Lee J. Recent advances in organelle-targeted fluorescent probes. Molecules 2021, 26, 217.

2020

71. Nam HY, Choi J, Kumar SD, Nielsen JE, Kyeong M, Wang S, Kang D, Lee Y, Lee J, Yoon MH, Hong S, Lund R, Jenssen H, Shin SY, Seo J. Helicity modulation improves selectivity of antimicrobial peptoids. ACS Infect. Dis. 2020, 6, 2732-2744

70. Nam HY**, Song D**, Eo J**, Choi N-E, Hong J-A, Hong KT, Lee J-S, Seo J*, Lee J* Activity-based probes for the high temperature requirement A serine proteases.. ACS Chem. Biol. 2020, 15, 2346-2354 (**co-first authors and *co-corresponding authors)

69. Lim JW, Lee J*, Pae AN* Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention.. BMB Rep. 2020, 53, 47-55. (*co-corresponding authors)

68. Kim S, Nam HY, Lee J*, Seo J* Mitochondrion-Targeting Peptides and Peptidomimetics: Recent Progress and Design Principles.. Biochemistry 2020, 59, 270-284. (*co-corresponding authors)

2019

67. Hoang VH, Ngo VTH, Cui M, Manh NV, Tran PT, Ann J, Ha HJ, Kim H, Choi K, Kim YH, Chang H, Macalino SJY, Lee J, Choi S, Lee J. Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer’s Agents by Structure-Based Design.. J. Med. Chem. 2019, 62, 8011-8027.

66. Yoon S, Kim SE, Kim JH, Yoon I, Tran PT, Ann J, Kim C, Byun WS, Lee S, Kim S, Lee J*, Lee J* Structure-activity relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of rapamycin complex 1 (mTORC1).. Bioorg. Med. Chem. 2019, 27, 1099-1109. (*co-corresponding authors)

2018

65. Elkamhawy A, Park JE, Hassan AHE, Pae AN, Lee J, Paik S, Park BG, Roh EJ. Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer’s disease.. Eur. J. Med. Chem. 2018, 157, 268-278.

64. Yoon S, Zuo D, Kim JH, Yoon I, Ann J, Kim SE, Cho D, Kim WK, Lee S, Lee J, Kim S, Lee J. Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.. Bioorg. Med. Chem. 2018, 26, 4073-4079.

63. Ngo VTH, Hoang V, Tran P, Van Manh N, Ann J, Kim E, Cui M, Choi S, Lee J, Kim H, Ha H, Choi K, Kim Y, Lee J. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer’s agents: Structure-activity relationship study of Arg-mimetic region. Bioorg. Med. Chem. 2018, 26, 3133-3144

62. Nam HY*, Hong JA*, Choi J, Shin S, Cho SK, Seo J, Lee J. Mitochondria-targeting peptoids. Bioconj. Chem. 2018, 29, 1669-1676. (*Co-first authors)

61. Hong JA, Kim MJ, Eoh J, Lee J. A turn-on fluorescent probe for live cell imaging of biothiols. Bull. Kor. Chem. Soc. 2018, 39, 425-426.

60. Ngo VTH, Hoang V, Tran P, Ann J, Cui M, Park G, Choi S, Lee J, Kim H, Ha H, Choi K, Kim Y, Lee J. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer’s agents: Structure-activity relationship study of Arg-mimetic region. Bioorg. Med. Chem. 2018, 26, 1035-1049.

59. Kim SM, Lee M, Lee SY, Lee SM, Kim EJ, Kim JS, Ann J, Lee J., Lee J. Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists. Eur. J. Med. Chem. 2018, 145, 413-424.

58. Elkamhawy A, Park JE, Hassan AH, Pae AN, Lee J., Park BG, Roh EJ. Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer’s disease.. Eur. J. Med. Chem. 2018, 144, 529-543.

57. Lee J., Kang D, Choi J, Huang W, Wadmen M, Barron AE, Seo J. Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids. Bioorg. Med. Chem. Lett. 2018, 28, 170-173.

56. Ha H, Kang DW, Kim HM, Kang JM, Ann J, Hyun HJ, Lee JH, Kim SH, Kim H, Choi K, Hong HS, Kim YH, Jo DG, Lee J., Lee J. Discovery of an Orally Bioavailable Benzofuran Analogue that Serves as a β-amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer’s Disease.. J. Med. Chem. 2018, 61, 396-402.

2017

55. Park JE, Elkamhawy A, Hassan AH, Pae AN, Lee J., Paik S, Park BG, Roh EJ. Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-β-induced toxicity.. Eur. J. Med. Chem. 2017, 141, 322-334.

54. Kim TH, Son WS, Morshed MN, Londhe AM, Jung SY, Park J, Park WK, Lim SM, Park KD, Cho SJ, Jeong KS, Lee J*, Pae AN* Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.. Eur. J. Med. Chem. 2017, 141, 240-256 (*co-corresponding authors)

53. Hong JA, Choi NE, La YK, Nam HY, Seo J, Lee J. Development of a smart activity-based probe to detect subcellular activity of asparaginyl endopeptidase in living cells.. Org. Biomol. Chem. 2017, 15, 8018-8022.

52. Park I, Viswanath ANI, Park BG, Jung SY, Park KD, No KT, Lee J., Pae AN. Discovery of Non-Peptidic Small Molecule Inhibitors of Cyclophilin D as Neuroprotective Agents in Ab-induced Mitochondrial Dysfunction. J. Comput. Aided Mol. Des. 2017, 31, 929-941.

51. Yoon S, Kim JH, Koh Y, Tran PT, Ann J, Yoon I, Jang J, Kim WK, Lee S, Lee J., Kim S, Lee J. Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.. Bioorg. Med. Chem. 2017, 25, 4145-4152

50. Elkamhawy A, Park JE, Hassan AH, Pae AN, Lee J., Park BG, Paik S, Do J, Park JH, Park KD, Moon B, Park WK, Cho H, Jeong DY, Roh EJ. Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2H)-ones: A novel class of TSPO ligands modulating amyloid-β-induced mPTP opening.. Eur. J. Pharm. Sci. 2017, 104, 366-381

49. Hoang V, Tran P, Cui M, Ngo VTH, Park J, Choi S, Lee J., Choi K, Cho H, Kim H, Ha H, Hong H, Kim Y, Lee J. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer’s Agent Based on Rational Design. J. Med. Chem. 2017, 60, 2573-2590

48. Elkamhawy A, Park JE, Hassan AH, Ra H, Pae AN, Lee J., Park BG, Moon B, Park HM, Roh EJ. Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.. Eur. J. Med. Chem. 2017, 128, 56-69

47. Kim TH, Yang HY, Park BG, Jung SY, Park JH, Park KD, Min SJ, Tae J, Yang H, Cho S, Song H, Mook-Jung I, Lee J*, Pae AN* Discovery of Benzimidazole Derivatives as Modulators of Mitochondrial Function: A Potential Treatment for Alzheimer’s Disease. Eur. J. Med. Chem. 2017, 125, 1172-1192 (*co-corresponding authors)

2016

46. Yoon S, Kim JH, Kim S, Jang J, Kim S, Moon H, Kim W, Lee S, Lee J., Kim S, Lee J. Discovery of leucyladenylate sulfamates as novel leucyl-tRNA (LRS)-targeted mTORC1 inhibitors. J. Med. Chem. 2016, 59, 10322-10328.

45. Kim SM, Lee M, Lee SY, Park E, Lee SM, Kim EJ, Han MY, Yoo T, Ann J, Yoon S, Lee J, Lee J. Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist.. J. Med. Chem. 2016, 59, 9150-9172

44. Cho NC, Seo SH, Kim D, Shin JS, Ju J, Seong J, Seo SH, Lee J., Lee KT, Kim YK, No KT, Pae AN. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist. J. Comput. Aided Mol. Des. 2016, 8, 625-637.

43. La YK, Hong JA, Jeong YJ, Lee J. A 1,8-naphthalimide-based chemosensor for dual-mode sensing: Colorimetric and fluorometric detection of multiple analytes. RSC Adv. 2016, 6, 84980-84105

42. Yoon S, Kim JH, Yoon I, Kim C, Kim SE, Koh Y, Jeong SJ, Lee J., Kim S, Lee J. Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor.. Bioorg. Med. Chem. Lett. 2016, 26, 3038-3041

41. Lee J. Mitochondrial drug targets in neurodegenerative diseases. , Bioorg. Med. Chem. Lett. 2016, 26, 714-720

40. Lee HR, Farhanullah, Lee J, Jajoo R, Kong SY, Shin JY, Kim JO, Lee J., Lee J, Kim HJ. Discovery of a Small Molecule that Enhances Astrocytogenesis by Activation of STAT3, SMAD1/5/8, and ERK1/2 via Induction of Cytokines in Neural Stem Cells.. ACS Chem. Neurosci. 2016, 7, 90-99

2015

39. Cho NC, Cha JH, Kim H, Kwak J, Kim D, Seo SH, Shin JS, Kim T, Park KD, Lee J., No KT, Kim YK, Lee KT, Pae AN. Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.. Bioorg. Med. Chem. 2015, 23, 7717-7727

38. Choi K, Lim KS, Shin J, Kim SH, Suh YG, Hong HS, Kim H, Ha HJ, Kim YH, Lee J., Lee J. 6-Phenoxy-2-phenylbenzoxazoles, novel inhibitors of receptor for advanced glycation end products (RAGE). Bioorg. Med. Chem. 2015, 23, 4919-4935

37. La YK, Choi NE, Chung S, Lee J. Thiophene-substituted Aza-BODIPYs as Near-Infrared Fluorophores. Bull. Kor. Chem. Soc. 2015, 36, 1747-1748

36. Lee J., Huang W, Broering JM, Barron AE, Seo J. Prostate tumor specific peptide-peptoid hybrid prodrugs. Bioorg. Med. Chem. Lett. 2015, 25, 2849-2952

35. Nam M, Kim T, Kwak J, Seo SH, Ko MK, Lim EJ, Min SJ, Cho YS, Keum G, Baek DJ, Lee J*, Pae AN* Discovery and biological evaluation of tetrahydrothieno[2,3-c]pyridine derivatives as selective metabotropic glutamate receptor 1 antagonists for the potential treatment of neuropathic pain. Eur. J. Med. Chem. 2015, 97, 245-258 (*co-corresponding author)

34. Cho GH, Kim T, Son WS, Seo SH, Min SJ, Cho YS, Keum G, Jeong KS, Koh HY, Lee J*, Pae AN* Synthesis and biological evaluation of aryl isoxazole derivatives as metabotropic glutamate receptor 1 antagonists: a potential treatment for neuropathic pain. Bioorg. Med. Chem. Lett. 2015, 25, 1324-1328 (*co-corresponding author)

2014

33. Elkamhawy A, Lee J., Park BG, Park I, Pae AN, Roh EJ. Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: design, synthesis, and molecular docking study. Eur. J. Med. Chem. 2014, 84, 466-475

2013

32. Choi MJ, Thorat DA, Jang JW, Yang H, No ES, Kim SJ, Lee J., Choo H, Lee CS, Ko SY, Lee J, Nam GS, Pae AN. Synthesis and biological evaluation of aryloxazole derivatives as vascular disrupting agents for cancer therapy. J. Med. Chem. 2013, 56, 9008-9018

31. Yoon HJ, Kong SY, Park MH, Cho Y, Kim SE, Shin JY, Jung S, Lee J., Farhanullah, Kim HJ, Lee J. Aminopropyl carbazole analogues as potent enhancers of neurogenesis. Bioorg. Med. Chem. 2013, 21, 7165-7174

30. Morell M, Nguyen Duc T, Willis AL, Syed S, Lee J., Deu E, Deng Y, Xiao J, Turk BE, Jessen JR, Weiss SJ, Bogyo M. Coupling Protein Engineering with Probe Design To Inhibit and Image Matrix Metalloproteinases with Controlled Specificity.. J. Am. Chem. Soc. 2013, 135, 9139-9148

29. Tran PT, Hoang VH, Thorat SA, Kim SE, Ann J, Chang YJ, Nam DW, Song H, Mook-Jung I, Lee J., Lee J. Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Bioorg. Med. Chem. 2013, 13, 3821-3830

28. Kang B, Chung S, Ahn YD, Lee J., Seo J. Porphyrin-Peptoid Conjugates: Face-to-Face Display of Porphyrins on Peptoid Helices. Org. Lett. 2013, 15, 1670-1673

27. Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD, Cho H, Park WK, Kwon OS, Cho YS, Ko M, Jang H, Choi K, Kim CH, Lee J*, Pae AN* Novel Pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity. Eur. J. Med. Chem. 2013, 63, 558-569 (*co-corresponding author)

26. Kim YS, Jung SH, Park BG, Ko MK, Jang HS, Choi K, Baik JH, Lee J., Lee JK, Pae AN, Cho YS, Min SJ. Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction. Eur. J. Med. Chem. 2013, 62, 71-83

25. Lee J*, Bogyo M* Target Deconvolution Techniques in Modern Phenotypic Profiling. Curr. Opin. Chem. Biol. 2013, 17, 118-126 (*co-corresponding author)

24. Edgington LE, Verdoes M, Ortega A, Withana NP, Lee J., Syed S, Bachmann MH, Blum G, Bogyo M. Functional Imaging of Legumain in Cancer Using a New Quenched Activity-Based Probe. J. Am. Chem. Soc. 2013, 135, 174-182

2012

23. Kim J, Lee J., Moon B, Mook-Jung I, Nam G, Keum G, Pae AN, Choo H. Pyridyl-urea Derivatives as Blockers of Abeta induced mPTP Opening for Alzheimer’s Disease. Bull. Korean Chem. Soc. 2012, 33, 3887-3889

22. Lee J. Cobalt(III) Complexes as Novel Matrix Metalloproteinase-9 Inhibitors. Bull. Korean Chem. Soc. 2012, 33, 2762-2764

21. Cho Y, Kim MS, Kim HS, Ann J, Lee J., Pearce LV, Pavlyukovets VA, Morgan MA, Blumberg PM, Lee J. The SAR analysis of TRPV1 agonists with the α-methylated B-region. Bioorg. Med. Chem. Lett. 2012, 22, 5227-5231.

20. Lee J*, Bogyo M* Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain. Bioorg. Med. Chem. Lett. 2012, 22, 1340-1343. (*co-corresponding author)

1999–2011

19. Ewald SE, Engel A, Lee J., Wang M, Bogyo M, Barton GM. Nucleic acid recognition by Toll-like receptors is coupled to processing by cathepsins and asparagine endopeptidase.. J. Exp. Med. 2011, 208, 643-651.

18. Lee J., Bogyo M. Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain. ACS Chem. Biol. 2010, 5, 233-243.

17. Harney AS, Lee J., Manus LM, Wang P, Ballweg DM, LaBonne C, Meade TJ. Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate. Proc. Nat. Acad. Sci. 2009, 106, 13667-13672.

16. Lee J., Burdette JE, MacRenaris KW, Mustafi D, Woodruff TK, Meade TJ. Rational design, synthesis, and biological evaluation of progesterone modified MRI contrast agents. Chem. Biol. 2007, 14, 824-834.

15. Lee J., Zylka MJ, Anderson DJ, Burdette JE, Woodruff TK, Meade TJ. A Steroid-Conjugated Contrast Agent for Magnetic Resonance Imaging of Cell Signaling.. J. Am. Chem. Soc. 2005, 127, 13164-13166.

14. Lee J., Jin M, Kang S-U, Kim SY, Lee J., Shin M, Hwang J, Cho S, Choi Y-S, Choi H-K, Kim S-E, Suh Y-G, Lee Y-S, Kim Y-H, Ha H-J, Toth A, Pearce LV, Tran R, Szabo T, Welter JD, Lundberg DJ, Wang Y, Lazar J, Pavlyukovets VA, Morgan MA, Blumberg PM. Analysis of structure-activity relationships for the ‘B-region’ of N-(4-t-butylbenzyl)-N’-[4-(methylsulfonylamino) benzyl]-thiourea analogues as TRPV1 antagonists.. Bioorg. Med. Chem. Lett. 2005, 15, 4143-4150.

13. Lee J., Kim SY, Lee J., Kang M, Kil M-J, Choi H-K, Jin M-K, Wang Y, Toth A, Pearce LV, Lundberg DJ, Tran R, Blumberg PM. Analysis of structure activity relationships with the N-(3-acyloxy-2-benzylpropyl)-N-[4-(methylsulfonylamino)benzyl] thiourea template for vanilloid receptor 1 antagonism.. Bioorg. Med. Chem. 2004, 12, 3411-3420.

12. Lee J., Kang S-U, Choi H-K, Lee J., Lim J-O, Kil M-J, Jin M-K, Kim K-P, Sung J-H, Chung S-J, Ha H-J, Kim Y-H, Pearce LV, Tran R, Lundberg DJ, Wang Y, Toth A, Blumberg PM. Analysis of structure activity relationships for the α-region of N-(3-acyloxy-2-benzylpropyl)-N-[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: discovery of an N-hydroxythiourea analogue with potent analgesic activity.. Bioorg. Med. Chem. Lett. 2004, 14, 2291-2297.

11. Lee J., Kim SY, Park S, Lim J-O, Kim J-M, Kang M, Lee J., Kang S-U, Choi H-K, Jin M-K, Welter JD, Szabo T, Tran R, Pearce LV, Toth A, Blumberg PM. Structure-activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding.. Bioorg. Med. Chem. 2004, 12, 1055-1069.

10. Park H-G, Choi J-Y, Choi S-H, Park M-K, Lee J., Suh Y-G, Cho H, Oh U, Lee J., Kang S-U, Lee J, Kim H-D, Park Y-H, Jeong YS, Choi JK, Jew S-S. N-4-Substituted-benzyl-N-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity.. Bioorg. Med. Chem. Lett. 2004, 14, 787-791.

9. Wang Y, Toth A, Tran R, Szabo T, Welter JD, Blumberg PM, Lee J., Kang S-U, Lim J-O, Lee J. High Affinity of Partial Agonists of Vanilloid Receptor.. Mol. Pharmacol. 2003, 64, 325-334.

8. Lee J., Lee J., Kang M, Shin M-Y, Kim J-M, Kang S-U, Lim J-O, Choi H-K, Suh Y-G, Park H-G, Oh U, Kim H-D, Park Y-H, Ha H-J, Kim Y-H, Toth A, Wang Y, Tran R, Pearce LV, Lundberg DJ, Blumberg PM. N-(3-Acyloxy-2-benzylpropyl)-N’-[4-(methylsulfonylamino) benzyl] thiourea Analogues: Novel Potent and High Affinity Antagonist and Partial Antagonists of the Vanilloid Receptor.. J. Med. Chem. 2003, 46, 3116-3126.

7. Wang Y, Szabo T, Welter JD, Toth A, Tran R, Lee J., Kang S-U, Suh Y-G, Blumberg PM, Lee J. High Affinity Antagonists of the Vanilloid Receptor.. Mol. Pharmacol. 2002, 62, 947-956.

6. Lee J., Lee J., Kang MS, Kim KP, Chung SJ, Blumberg PM, Yi JB, Park YH. Phenolic Modification as an Approach to Improve the Pharmacology of the 3-Acyloxy-2-benzylpropyl Homovanillic Amides and Thioureas, a Promising Class of Vanilloid Receptor Agonist and Analgesics. Bioorg. Med. Chem. 2002, 10, 1171-1179.

5. Lee J., Lee J., Szabo T, Gonzalez AF, Welter JD, Blumberg PM. N-(3-Acyloxy-2-benzylpropyl)-N-Dihydroxy Tetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands. Bioorg. Med. Chem. 2001, 9, 1713-1720.

4. Lee J., Lee J., Kim J, Kim SY, Chun MW, Cho H, Hwang SW, Oh U, Park YH, Marquez VE, Beheshti M, Szabo T, Blumberg PM. N-(3-Acyloxy-2-benzylpropyl)-N-(4-hydroxy-3-methoxy benzyl)thiourea Derivatives as Potent Vanilloid Receptor Agonists and Analgesics. Bioorg. Med. Chem. 2001, 9, 19-32.

3. Lee J., Park SU, Kim JY, Kim JK, Lee J., Oh U, Marquez VE, Beheshti M, Wang QJ, Modarres S, Blumberg PM. N-Acyloxy-2-phenalkylpropyl Amides and Esters of Homovanillic Acid as Novel Vanilloid receptor Agonists. Bioorg. Med. Chem. Lett. 1999, 9, 2909-2914.

2. Chun KS, Sohn Y, Kim HS, Kim OH, Park KK, Lee JM, Lee J., Lee J, Moon A, Lee SS, Surh YJ. Anti-tumor Promoting Potential of Naturally Occurring Diarylheptanoids Stucturally Related to Curcumin. Mutat. Res. 1999, 428, 49-57.

1. Lee J., Lee J. A Facile and Practical Synthesis of Capsazepine, A Vanilloid Receptor Antagonist.. Synthetic Commun. 1999, 29, 4127-4140.